Polycystin-1 Is a Crucial Regulator of BIN1 Expression and T-Tubule Remodeling Associated with the Development of

Magda C Díaz-Vesga1,2,3, Raúl Flores-Vergara1,2,4, Jaime A Riquelme4,5

  • 1Programa de Fisiología y Biofísica, ICBM, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile.

Insights

Polycystin-1 (PC1) in heart cells is crucial for preventing dilated cardiomyopathy. Reduced PC1 impairs BIN1 expression and T-tubule structure, leading to heart failure in autosomal dominant polycystic kidney disease (ADPKD) models.

Area of Science:

  • Cardiovascular Pathophysiology
  • Molecular Cardiology
  • Genetics of Kidney Disease

Background:

  • Cardiomyopathy is frequent in autosomal dominant polycystic kidney disease (ADPKD) patients, irrespective of kidney function or blood pressure.
  • The specific role of cardiomyocyte polycystin-1 (PC1) in cardiovascular disease is not well understood.
  • PC1 influences BIN1, a protein vital for T-tubule structure, and its dysregulation can cause cardiac issues.

Purpose of the Study:

  • To investigate the role of cardiomyocyte-specific PC1 in heart failure (HF) development.
  • To explore the potential mechanism involving reduced BIN1 expression and T-tubule remodeling.
  • To analyze the impact of PC1 deficiency on cardiac function and survival in a mouse model.

Main Methods:

  • Utilized a cardiomyocyte-specific PC1-silenced (PC1-KO) mouse model.
  • Assessed cardiac function using echocardiography.
  • Quantified BIN1 mRNA, protein levels, and isoform expression.
  • Examined T-tubule structure and plasma BIN1 levels.

Main Results:

  • PC1-KO mice showed impaired cardiac function and developed dilated cardiomyopathy, with sudden death observed.
  • Decreased total BIN1 expression and altered BIN1 isoform ratios were noted in PC1-KO mice.
  • T-tubule remodeling correlated with reduced PC1-BIN1 expression and HF development.

Conclusions:

  • Reduced PC1 expression in cardiomyocytes leads to dilated cardiomyopathy.
  • Diminished BIN1 expression and T-tubule remodeling are key mechanisms in PC1-deficient cardiomyopathy.
  • PC1's positive modulation of BIN1 offers a potential therapeutic target for ADPKD-related cardiomyopathy.

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
19
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
30
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
36
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
23
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
17
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
22